GLP1R and diabetes mellitus: Given the therapeutic potential of GLP-1 receptor agonists, including the reduction of cardiovascular events and cardiovascular mortality in high-risk patients with diabetes [6,7,8,9], it seems promising to further explore the cardiovascular function of other gut-derived peptides.